home / stock / lpcn / lpcn articles
No one has written and article on Lipocine Inc., stock symbol LPCN. Be the first to contribute and write an article.
News, Short Squeeze, Breakout and More Instantly...
2024-04-11 09:01:37 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Lipocine Inc. (NASDAQ: LPCN ) results from a Phase 2 clinical trial including LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, which sho...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fa...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52...